No black box warning on record for Emgality

As of the latest FDA labeling reviewed, Emgality (galcanezumab-gnlm) does not carry a black box warning. Standard warnings and precautions still apply — see the full Emgality medicine page for the complete safety profile.

Other warnings & precautions

Hypersensitivity reactions including anaphylaxis have been reported — discontinue immediately if these occur.
Severe constipation requiring medical intervention has been reported.
Post-marketing: reports of hair loss — discuss with prescriber if this occurs.

No black box warning on record for Emgality

Other warnings & precautions

Hypersensitivity reactions including anaphylaxis have been reported — discontinue immediately if these occur.
Severe constipation requiring medical intervention has been reported.
Post-marketing: reports of hair loss — discuss with prescriber if this occurs.

Emgality Black Box Warning

No black box warning on record for Emgality

Other warnings & precautions

Emgality Black Box Warning

No black box warning on record for Emgality

Other warnings & precautions